Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
Authors:
- 31 March 2003
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 21 (5) , 546-552
Abstract
Addition of polyethylene glycol to protein (PEGylation) to improve stability and other characteristics is mostly nonspecific and may occur at all lysine residues, some of which may be within or near an active site. Resultant PEGylated proteins are heterogeneous and can show markedly lower bioactivity. We attempted to develop a strategy for site-specific mono-PEGylation using tumor necrosis factor-α (TNF-α). We prepared phage libraries expressing TNF-α mutants in which all the lysine residues were replaced with other amino acids. A fully bioactive lysine-deficient mutant TNF-α (mTNF-α-Lys(−)) was isolated by panning against TNF-α-neutralizing antibody despite reports that some lysine residues were essential for its bioactivity. mTNF-α-Lys(−) was site-specifically mono-PEGylated at its N terminus. This mono-PEGylated mTNF-α-Lys(−), with superior molecular uniformity, showed higher bioactivity in vitro and greater antitumor therapeutic potency than randomly mono-PEGylated wild-type TNF-α. These results suggest the usefulness of the phage display system for creating functional mutant proteins and of our site-specific PEGylation approach.Keywords
This publication has 30 references indexed in Scilit:
- Site-directed polyethylene glycol modification of trichosanthin: Effects on its biological activites, pharmacokinetics, and antigenicityLife Sciences, 1999
- Selective Enhancement by Tumor Necrosis Factor‐α of Vascular Permeability of New Blood Vessels Induced with Agarose Hydrogel‐entrapped Meth‐A Fibrosarcoma CellsJapanese Journal of Cancer Research, 1996
- Organ targeting In vivo using phage display peptide librariesNature, 1996
- Phase I Study of Tumor Necrosis Factor Plus Actinomycin D in Patients with Androgenindependent Prostate CancerCancer Biotherapy, 1995
- L-Asparaginase and PEG Asparaginase— Past, Present, and FutureLeukemia & Lymphoma, 1993
- Mutational analysis of structure—activity relationships in human tumor necrosis factor-alphaProtein Engineering, Design and Selection, 1990
- Structure of tumour necrosis factorNature, 1989
- Phase I study of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987
- Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion SurfaceScience, 1985
- Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude miceInternational Journal of Cancer, 1984